Table 1.
M6 | M7 | M24 | M25 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Subject | mAb | mAb IC50 | Plasma IC50 | Subject | mAb | mAb IC50 | Plasma IC50 | Subject | mAb | mAb IC50 | Plasma IC50 | Subject | mAb | mAb IC50 | Plasma IC50 |
11 | HPV-16.77 | >333 nM | 7350 | 11 | HPV-16.55 | 1.6 pM | 414000 | 11 | HPV-16.95 | >333 nM | 33500 | 11 | HPV-16.128 | >333 nM | 74100 |
HPV-16.78 | >333 nM | HPV-16.56 | 6.2 nM | HPV-16.96 | 5.3 pM | HPV-16.129 | 30.2 pM | ||||||||
HPV-16.79 | >333 nM | HPV-16.57 | 0.2 pM | HPV-16.97 | 1.0 pM | HPV-16.130 | 6.8 pM | ||||||||
HPV-16.80 | 39.1 pM | HPV-16.58 | 14.2 pM | HPV-16.98 | >333 nM | 12 | HPV-16.131 | 15.9 pM | 172000 | ||||||
HPV-16.81 | >333 nM | HPV-16.59 | 48.4 nM | HPV-16.99 | 8.5 pM | HPV-16.132 | 21.2 pM | ||||||||
13 | HPV-16.83 | >333 nM | 8750 | HPV-16.60 | 0.4 pM | HPV-16.166 | 30.7 pM | HPV-16.133 | >333 nM | ||||||
HPV-16.84 | 6.2 pM | HPV-16.61 | 0.2 pM | 12 | HPV-16.100 | 36 pM | 8070 | HPV-16.134 | >333 nM | ||||||
HPV-16.85 | >333 nM | HPV-16.62 | >333 nM | 13 | HPV-16.101 | >333 nM | 611 | HPV-16.135 | 3.0 pM | ||||||
HPV-16.86 | >333 nM | HPV-16.63 | 3.4 pM | 14 | HPV-16.102 | >333 nM | 4310 | HPV-16.136 | 2.2 pM | ||||||
HPV-16.87 | >333 nM | HPV-16.64 | 5.1 pM | 13 | HPV-16.137 | 7.0 pM | 155000 | ||||||||
14 | HPV-16.82 | 8.1 pM | 18500 | HPV-16.65 | >333 nM | HPV-16.138 | 23.4 pM | ||||||||
HPV-16.66 | 38.1 pM | HPV-16.139 | 75.6 pM | ||||||||||||
HPV-16.67 | >333 nM | HPV-16.140 | >333 nM | ||||||||||||
12 | HPV-16.68 | 6.3 nM | 105000 | HPV-16.141 | 1.1 pM | ||||||||||
HPV-16.69 | 1.7 pM | HPV-16.142 | 68.3 nM | ||||||||||||
HPV-16.70 | 3.3 pM | HPV-16.143 | 0.7 pM | ||||||||||||
HPV-16.71 | 6.7 pM | HPV-16.144 | 0.9 pM | ||||||||||||
HPV-16.72 | 3.9 pM | HPV-16.145 | 6.8 pM | ||||||||||||
HPV-16.74 | 0.7 pM | HPV-16.146 | 3.8 pM | ||||||||||||
13 | HPV-16.90 | 1.2 pM | 10700 | HPV-16.147 | 0.9 pM | ||||||||||
14 | HPV-16.73 | 1.8 pM | 122000 | HPV-16.148 | 16.9 pM | ||||||||||
HPV-16.75 | >333 nM | HPV-16.149 | 0.1 nM | ||||||||||||
HPV-16.150 | 5.0 pM | ||||||||||||||
HPV-16.151 | 6.0 pM | ||||||||||||||
HPV-16.152 | 11.9 pM | ||||||||||||||
14 | HPV-16.153 | >333 nM | 87900 | ||||||||||||
HPV-16.154 | 0.8 pM | ||||||||||||||
HPV-16.155 | 11.6 pM | ||||||||||||||
HPV-16.156 | 6.7 nM | ||||||||||||||
HPV-16.157 | 24.3 pM | ||||||||||||||
HPV-16.158 | 1.9 pM | ||||||||||||||
HPV16.159 | 1.0 pM | ||||||||||||||
HPV16.160 | 67.0 pM | ||||||||||||||
HPV16.161 | 8.1 pM | ||||||||||||||
HPV16.162 | 2.8 pM | ||||||||||||||
HPV16.163 | 2.9 pM | ||||||||||||||
HPV-16.164 | 0.4 pM |
At each indicated time point, monoclonal antibodies (mAbs) cloned from human papillomavirus type 16 (HPV-16)–specific Bmem are shown alongside their neutralization potency, or the concentration at which they achieved half-maximal virus inhibition. No mAbs were successfully cloned from the few HPV-16+ Bmem isolated from subject 12 at month (M) 6. The levels of neutralizing anti–HPV-16 Abs in blood, or plasma dilution at which half-maximal virus inhibition (IC50) occurred, are also shown for comparison. The frequency of neutralizing mAbs cloned from HPV-16+ Bmem at each time point was ~31% (M6), ~82% (M7), ~56% (M24), and ~86% (M25). Neutralization potencies for mAbs cloned from Bmem at M6W1 and M24W1 are shown in Supplementary Table 1.